Literature DB >> 22867967

Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia.

Nian Liu1, Carlo Napolitano, Luigi A Venetucci, Silvia G Priori.   

Abstract

Recent studies have shown that flecainide may be an effective therapy to prevent life-threatening arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. Several hypotheses have been advanced to explain the antiarrhythmic mechanism of flecainide, including Na(+) channel blockade and a direct inhibitory action on the ryanodine receptor. In this article, we review the current literature on the topic and summarize the elements of the existing debate.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22867967     DOI： 10.1016/j.tcm.2012.06.008

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN： 1050-1738            Impact factor:   6.677


  7 in total

1.  Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Derek S Steele; Hyun-Seok Hwang; Björn C Knollmann
Journal:  Cardiovasc Res       Date:  2013-03-19       Impact factor: 10.787

Review 2.  Patient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening In Catecholaminergic Polymorphic Ventricular Tachycardia.

Authors:  Ronen Ben Jehuda; Lili Barad
Journal:  J Atr Fibrillation       Date:  2016-08-31

3.  CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.

Authors:  E Di Pasquale; F Lodola; M Miragoli; M Denegri; J E Avelino-Cruz; M Buonocore; H Nakahama; P Portararo; R Bloise; C Napolitano; G Condorelli; S G Priori
Journal:  Cell Death Dis       Date:  2013-10-10       Impact factor: 8.469

4.  In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Pei-Chi Yang; Jonathan D Moreno; Christina Y Miyake; Steven B Vaughn-Behrens; Mao-Tsuen Jeng; Eleonora Grandi; Xander H T Wehrens; Sergei Y Noskov; Colleen E Clancy
Journal:  J Physiol       Date:  2015-12-30       Impact factor: 5.182

5.  Hyperactive ryanodine receptors in human heart failure and ischaemic cardiomyopathy reside outside of couplons.

Authors:  Eef Dries; Demetrio J Santiago; Guillaume Gilbert; Ilse Lenaerts; Bert Vandenberk; Chandan K Nagaraju; Daniel M Johnson; Patricia Holemans; H Llewelyn Roderick; Niall Macquaide; Piet Claus; Karin R Sipido
Journal:  Cardiovasc Res       Date:  2018-09-01       Impact factor: 10.787

Review 6.  Ventricular Arrhythmias in Ischemic Cardiomyopathy-New Avenues for Mechanism-Guided Treatment.

Authors:  Matthew Amoni; Eef Dries; Sebastian Ingelaere; Dylan Vermoortele; H Llewelyn Roderick; Piet Claus; Rik Willems; Karin R Sipido
Journal:  Cells       Date:  2021-10-01       Impact factor: 6.600

Review 7.  The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia.

Authors:  Yukun Li; Xiaodong Peng; Rong Lin; Xuesi Wang; Xinmeng Liu; Rong Bai; Changsheng Ma; Ribo Tang; Yanfei Ruan; Nian Liu
Journal:  Front Physiol       Date:  2022-03-09       Impact factor: 4.566
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.